非酒精性脂肪性肝病(NAFLD)患者的肌少症与进展性纤维化相关
该研究基于2017-2018年美国国家健康与营养调查(NHANES)数据,纳入2422名参与者,评估NAFLD患者中肌少症与肝纤维化的关联。结果显示,合并肌少症的NAFLD患者显著纤维化和进展性纤维化发生率更高,且NAFLD与肌少症对显著纤维化的交互作用归因比例达55%。结论认为合并肌少症的NAFLD患者存在显著和进展性纤维化风险。
要点
- 合并肌少症的NAFLD患者显著纤维化发生率为18.3%,进展性纤维化为7.1%。
- 无肌少症时,NAFLD与显著纤维化风险升高相关(OR 2.18,95%CI 0.92-5.19)。
- 有肌少症时,NAFLD与显著纤维化风险升高相关(OR 11.27,95%CI 2.79-45.56)。
核心结论
- 合并肌少症的NAFLD患者存在显著纤维化和进展性纤维化风险。
- 增加体力活动和健康饮食以改善肌少症性NAFLD可能降低显著纤维化风险。
研究设计与样本
- 研究采用2017-2018年美国国家健康与营养调查(NHANES)数据。
- NAFLD通过瞬时弹性成像定义,排除其他肝病原因或过量饮酒。
主要发现
- 在总队列(N=2422)中,18.9%存在肌少症,9.8%存在肥胖性肌少症,43.6%存在NAFLD,7.0%存在显著纤维化,2.0%存在进展性纤维化。
- 50.1%既无肌少症也无NAFLD,6.3%有肌少症无NAFLD,31.1%有NAFLD无肌少症,12.5%有NAFLD合并肌少症。
- 与无NAFLD且无肌少症的个体相比,合并肌少症的NAFLD个体显著纤维化发生率更高(18.3% vs 3.2%),进展性纤维化发生率更高(7.1% vs 0.2%)。
- 无肌少症时,与无NAFLD个体相比,NAFLD个体显著纤维化风险升高(OR 2.18;95%CI 0.92-5.19)。
- 有肌少症时,NAFLD与显著纤维化风险升高相关(OR 11.27;95%CI 2.79-45.56),且独立于代谢组分。
关键数值与推荐
- 显著纤维化定义为肝硬度大于8.0 kPa。
- 进展性纤维化定义为肝硬度大于13.1 kPa。
- 肌少症采用美国国立卫生研究院基金会(Foundation for the National Institutes of Health)定义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) and sarcopenia can be associated with advanced liver disease. Our aim was to assess the association between sarcopenia and the risk of fibrosis among patients with NAFLD. METHODS: We used the National Health and Nutrition Examination Survey (2017-2018). NAFLD was defined by transient elastography without other causes of liver disease or excessive alcohol use. Significant fibrosis (SF) and advanced fibrosis (AF) were defined by liver stiffness greater than 8.0 kPa and greater than 13.1 kPa, respectively. Sarcopenia was defined using the Foundation for the National Institutes of Health definition. RESULTS: Of the total cohort (N = 2422), 18.9% had sarcopenia, 9.8% had obese sarcopenia, 43.6% had NAFLD, 7.0% had SF, and 2.0% had AF. Moreover, 50.1% had neither sarcopenia nor NAFLD, 6.3% had sarcopenia without NAFLD, 31.1% had NAFLD without sarcopenia, and 12.5% had NAFLD with sarcopenia. Compared with individuals without NAFLD or sarcopenia, individuals with sarcopenic NAFLD had higher rates of SF (18.3% vs 3.2%) and AF (7.1% vs 0.2%). In the absence of sarcopenia, compared with individuals without NAFLD, individuals with NAFLD have a significantly increased risk of SF (odds ratio, 2.18; 95% CI, 0.92-5.19). In the presence of sarcopenia, NAFLD was associated with an increased risk of SF (odds ratio, 11.27; 95% CI, 2.79-45.56). This increase was independent of metabolic components. The proportion of SF that is attributable to the interaction of NAFLD and sarcopenia was 55% (attributable proportion, 0.55; 95% CI, 0.36-0.74). Increased leisure time physical activity was associated with a lower risk of sarcopenia. CONCLUSIONS: Patients with sarcopenic NAFLD are at risk for SF and AF. Increased physical activity and a healthy diet targeted to improve sarcopenic NAFLD could reduce the risk of significant fibrosis.
引用
- Harring M, Golabi P, Paik JM, et al. Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis. Clin Gastroenterol Hepatol. 2023. PMID: 36848980. doi:10.1016/j.cgh.2023.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。